
49482-Review.doc

FAQ



Name of Journal: World Journal of Gastroenterology

Manuscript NO: 49482

Manuscript Type: ORIGINAL ARTICLE


Observational Study

Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment

Gil-García AI et al. HCC-related HBV mutants in patients in grey zone

Ana I Gil-García, Antonio Madejón, Irene Francisco-Recuero, Ana López-López, Emiliana Villafranca, Miriam Romero, Araceli García, Antonio Olveira, Rocío Mena, Juan R Larrubia, Javier García-Samaniego







AII

Images

Videos

翻译成中文

关闭取词

1,160,000 Results

Any time *

Antiviral therapies for hepatitis B virus-related ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385532

Apr 07, 2015 · Timely initiation of antiviral **treatment** is not only essential for preventing the incidence of HCC in chronic hepatitis **B patients**, but also important for reducing **HBV** reactivation, improving liver function, reducing or delaying HCC recurrence, and prolonging overall survival of **HBV**-related HCC **patients** after curative and palliative therapies.

Cited by: 3 Author: Yuan-Qing Zhang, Jin-Sheng Guo

Publish Year: 2015

Hepatitis B virus genotypes: Global distribution and ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017058

May 14, 2014 · Core tip: Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease and death worldwide. The clinical course and consequences of HBV infection are affected by several factors such as viral load, mutation, host, environment, and viral genotypes.

Cited by: 175 Author: Mustafa Sunbul

Publish Year: 2014

[PDF] Management of Chronic Hepatitis B in Asian Americans

www.chronicliverdisease.org/disease_focus/ppts/hbv/Management_of_Chronic_HepatitisB_in...

Patients in the gray zone - assess for antiviral therapy: -HBeAg- chronic hepatitis • HBV DNA >2000 IU/mL, ALT ≤ULN (of the clinical laboratory) -HBeAg +/- chronic hepatitis • HBV DNA ≤2000 IU/mL, ALT >ULN (of the clinical laboratory) -Assess for antiviral therapy • Liver biopsy if available; if not, use Risk Impact Score

Prevalence of hepatitis B virus DNA polymerase mutations ...

https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2009.04151.x

Hepatitis B virus (HBV) is the leading cause of chronic liver disease worldwide. 1, 2 Baseline HBV DNA is highly predictive of disease progression with development of cirrhosis and liver cancer. 3 At least in patients with advanced fibrosis, treatment with anti-viral therapy can decrease the risk of disease progression to cirrhosis and ...

Cited by: 16 Author: M. H. Nguyen, R. T. Garcia, H. N. Trinh, ...

Publish Year: 2009

Hepatitis B viral factors in HBeAg-Negative carriers with ...

https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.21585

Apr 26, 2007 - Thus, the clinical spectrum of HBeAg-negative chronic HBV infection may range from inactive carrier to aggressive chronic hepatitis with or without cirrhosis. 2 The differential diagnosis of

Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey



AII

Images

Videos

翻译成中文

关闭取词

9.540 Results

Any time ▼

High incidence of treatment-induced and vaccine-escape ...

https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26374

Mar 06, 2013 · Anti-hepatitis B virus (HBV) nucleos(t)ides analogs (NA) exert selective pressures on polymerase (pol) and surface (S) genes, inducing treatment resistance and increasing the risk of vaccine escape mutants. The rate of emergence for these mutations is largely unknown in patients coinfected with human immunodeficiency virus (HIV) and HBV ...

Cited by: 28 Author: Karine Lacombe, Karine Lacombe, Ander...

Publish Year: 2013

Hepatitis B Virus (HBV) Infection in Liver Disease ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003639

Objectives: To determine the prevalence of Hepatitis B Surface antigen (HBsAg) in patients attending the Hepatology Out Patient Department (OPD) of a tertiary care hospital and to compare the routinely used HBsAg detection kit with the mutant detection kit to find out the presence of mutants in a given setting. Materials and Methods: A cross-sectional study was carried out in adult patients ...

Cited by: 3 Author: Shweta P. Kamat, Preeti R. Mehta, Supri...

Publish Year: 2014

Hepatitis B Virus-Related Hepatocellular Carcinoma ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645579

Jul 18, 2014 - Infection with the hepatitis B virus (HBV) is one of most important risk factors for hepatocellular carcinoma (HCC). Indeed, HBV is considered a group 1 human carcinogen and is a highly oncogenic agent. HBV cannot be effectively controlled or completely eliminated, so ...

Cited by: 7 Author: Hong-Zhi Xu, Yun-Peng Liu, Bayasi Gulen...

Publish Year: 2014

High mutation prevalence of precore and basal core ...

https://www.sciencedirect.com/science/article/pii/S1590865819306784

Jul 15, 2019 - It is estimated that "250 million people worldwide are chronically infected with hepatitis B virus (HBV), among whom "25–40% individuals will eventually develop HBV-related liver cirrhosis and hepatocellular carcinoma.

Author: Yuqian Luo, Mingjie Pan, Mingzhe Nin... Publish Year: 2019

Hepatitis B virus: Prevalence of precore/core promoter ...



国际版

Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in gr



All

Images

Videos

翻译成中文

关闭取词

30,700 Results

Any time ▼

High incidence of treatment-induced and vaccine-escape ...

https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.26374

Mar 06, 2013 · Anti-hepatitis B virus (HBV) nucleos(t)ides analogs (NA) exert selective pressures on polymerase (pol) and surface (S) genes, inducing treatment resistance and increasing the risk of vaccine escape mutants. The rate of emergence for these mutations is largely unknown in patients coinfected with human immunodeficiency virus (HIV) and HBV ...

Cited by: 28 Author: Karine Lacombe, Karine Lacombe, Anders ...

Publish Year: 2013

Hepatitis B Virus-Related Hepatocellular Carcinoma ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645579

Jul 18, 2014 - Infection with the **hepatitis B virus** (HBV) is one of most important risk factors for hepatocellular carcinoma (HCC). Indeed, HBV is considered a group 1 human carcinogen and is a highly oncogenic agent. HBV cannot be effectively controlled or completely eliminated, so ...

Cited by: 7 Author: Hong-Zhi Xu, Yun-Peng Liu, Bayasi Guleng, ...

Publish Year: 2014

Prevalence of hepatitis B and C infections in ...

https://f1000research.com/articles/5-1910 •

Patients with chronic renal failure (CRF) on hemodialysis constitute a population at risk of HBV and HCV infections. Objective: Determining prevalence of the surface antigen of hepatitis B virus (HBsAg) and antibodies to hepatitis C virus (anti-HCV) in patients who attended dialysis units in the city of ...

Cited by: 1 Author: Karina Salvatierra, Hector Florez

Publish Year: 2016

Hepatitis B virus: Prevalence of precore/core promoter ...

https://www.researchgate.net/publication/10572252_Hepatitis_B_virus_Prevalence_of...

Download Citation on ResearchGate | Hepatitis B virus: Prevalence of precore/core promoter mutants in different clinical categories of Indian patients | To determine the association of precore ...

Molecular characterization of hepatitis B virus from ...

https://www.sciencedirect.com/science/article/pii/S1201971216000291

The phylogenetic tree was based on a 943-nucleotide (nt) fragment of the hepatitis B virus genome encoding the reverse transcriptase/hepatitis B surface antigen (nt 131–1,073 in the reference sequence, GenBank accession no. AF405706). The HBV DNA from isolates obtained in this study is indicated by a boldface white font on a black background.